parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	genetic association 0.04 (overall 0.35)	0.04
cell type Human Protein Atlas	cell type enhanced in oligodendrocyte progenitor cells (730 nCPM)	1.00
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 0883

ZNF462 in dopamine neurons, braak-0.47 (p 0.204) → +0.11 (p 0.784)receipt 0892
ZNF462 in oligodendrocytes, braak-0.05 (p 0.892) → +0.46 (p 0.209)receipt 0891

receipt 0892: ZNF462 in dopamine neurons, braak

power: full sample -0.16 (p 0.538, n 18), 95% CI -0.58 to +0.34. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.12 (p 0.633, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.06 (p 0.820, n 18). could be the mix.
skeptic: leave-one-out range -0.32 to -0.05, sign flips 0; without severely affected donors -0.16 (p 0.538, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ZNF462 in dopamine neurons.

case closed: nothing better to follow up.

receipt 0891: ZNF462 in oligodendrocytes, braak

power: full sample +0.13 (p 0.615, n 18), 95% CI -0.36 to +0.56. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.14 (p 0.585, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.16 (p 0.521, n 18). could be the mix.
skeptic: leave-one-out range +0.03 to +0.27, sign flips 0; without severely affected donors +0.13 (p 0.615, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ZNF462 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts